Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug 
development efforts

Rein, Theo

doi:10.1002/jcb.30166

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts

MPS-Authors

/persons/resource/persons80489

Rein, Theo
Dept. Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Rein, T. (2021). Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. JOURNAL OF CELLULAR BIOCHEMISTRY, e12775. doi:10.1002/jcb.30166.

Cite as: https://hdl.handle.net/21.11116/0000-0009-724A-4

Abstract

Drug repurposing is an attractive option for identifying new treatment strategies, in particular in extraordinary situations of urgent need such as the current coronavirus disease 2019 (Covid-19) pandemic. Recently, the World Health Organization announced testing of three drugs as potential Covid-19 therapeutics that are known for their dampening effect on the immune system. Thus, the underlying concept of selecting these drugs is to temper the potentially life-threatening overshooting of the immune system reacting to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This viewpoint discusses the possibility that the impact of these and other drugs on autophagy contributes to their therapeutic effect by hampering the SARS-CoV-2 life cycle.